Exchange: NASDAQ Sector: Healthcare Industry: Medical Devices
Current Signal: BUY (auto-tracking)
-2.49% $13.29
America/New_York / 28 mar 2024 @ 12:28
FUNDAMENTALS | |
---|---|
MarketCap: | 376.70 mill |
EPS: | -1.270 |
P/E: | -10.46 |
Earnings Date: | May 01, 2024 |
SharesOutstanding: | 28.34 mill |
Avg Daily Volume: | 0.0930 mill |
RATING 2024-03-28 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Strong Sell | |
Return On Asset: | Neutral | |
DE: | Strong Buy | |
P/E: | Strong Sell | |
Price To Book: | Strong Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -10.46 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.05x |
Company: PE -10.46 | industry: PE 222.16 |
DISCOUNTED CASH FLOW VALUE |
---|
N/A |
N/A |
Expected Trading Range (DAY) |
---|
$ 12.00 - 14.58 ( +/- 9.72%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-02-27 | Morrell Martha | Buy | 12 500 | Common Stock |
2024-02-27 | Morrell Martha | Buy | 24 950 | Stock Option (Right to Buy) |
2024-02-27 | Kuhn Rebecca | Buy | 12 500 | Common Stock |
2024-02-27 | Kuhn Rebecca | Buy | 24 950 | Stock Option (Right to Buy) |
2024-02-27 | Becker Joel | Buy | 104 720 | Stock Option (Right to Buy) |
INSIDER POWER |
---|
84.55 |
Last 97 transactions |
Buy: 23 073 006 | Sell: 13 399 644 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $13.29 (-2.49% ) |
Volume | 0.0064 mill |
Avg. Vol. | 0.0930 mill |
% of Avg. Vol | 6.88 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:32 | buy | $16.95 | N/A | Active |
---|
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.